Estudios
I+D+I
Institución
Internacional
Vida Universitaria
Repositorio Institucional de Documentos
Buscar
Enviar
Personalizar
Sus alertas
Sus carpetas
Sus búsquedas
Ayuda
EN
/
ES
Página principal
>
Artículos
> Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model
Estadísticas de uso
Gráficos
Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model
Biccler, J.
;
Bollaerts, K.
;
Vora, P.
;
Sole, E.
;
García Rodriguez, L.A.
;
Lanas, A.
(Universidad de Zaragoza)
;
Langley, R.E.
;
Soriano Gabarró, M.
Resumen:
Background: Low-dose aspirin therapy reduces the risk of cardiovascular disease and may have a positive effect on the prevention of colorectal cancer. We evaluated the population-level expected effect of regular low-dose aspirin use on cardiovascular disease (CVD), colorectal cancer (CRC), gastrointestinal bleeding, symptomatic peptic ulcers, and intracranial hemorrhage, using a microsimulation study design. Methods: We used individual-level state transition modeling to assess the impact of aspirin in populations aged 50–59 or 60–69 years old indicated for low-dose aspirin usage for primary or secondary CVD prevention. Model parameters were based on data from governmental agencies from the UK or recent publications. Results: In the 50–59 years cohort, a decrease in incidence rates (IRs per 100 000 person years) of non-fatal CVD (-203 and -794) and fatal CVD (-97 and-381) was reported in the primary and secondary CVD prevention setting, respectively. The IR reduction of CRC (-96 and -93) was similar for primary and secondary CVD prevention. The IR increase of non-fatal (116 and 119) and fatal safety events (6 and 6) was similar for primary and secondary CVD prevention. Similar results were obtained for the 60–69 years cohort. Conclusions: The decrease in fatal CVD and CRC events was larger than the increase in fatal safety events and this difference was more pronounced when low-dose aspirin was used for secondary compared to primary CVD prevention. These results provide a comprehensive image of the expected effect of regular low-dose aspirin therapy in a UK population indicated to use aspirin for CVD prevention. © 2021
Idioma:
Inglés
DOI:
10.1016/j.ijcha.2021.100851
Año:
2021
Publicado en:
IJC Heart and Vasculature
36 (2021), 100851 [8 pp]
ISSN:
2352-9067
Factor impacto CITESCORE:
3.3 -
Medicine
(Q2)
Factor impacto SCIMAGO:
0.803 -
Cardiology and Cardiovascular Medicine
(Q2)
Tipo y forma:
Artículo (Versión definitiva)
Área (Departamento):
Area Medicina
(
Dpto. Medicina, Psiqu. y Derm.
)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2022-09-08-11:57:48)
Enlace permanente:
Copiar
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Volver a la búsqueda
Registro creado el 2022-08-17, última modificación el 2022-09-08
Versión publicada:
PDF
Valore este documento:
Rate this document:
1
2
3
4
5
(Sin ninguna reseña)
Añadir a una carpeta personal
Exportar como
BibTeX
,
MARC
,
MARCXML
,
DC
,
EndNote
,
NLM
,
RefWorks